Drug discovery

Until 1981, pharmaceutical industry was dominated by the likes of Johnson & Johnson, Pfizer, and Merck -- all of which were established in the mid-1800s. Things were about to change. Recombinant DNA was the hot technology of the early 1980s. Genentech had just gone public after cloning insulin a...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical Executive 2006-08, Vol.26 (8), p.134
Main Author: Hrusovsky, Kevin
Format: Magazinearticle
Language:English
Subjects:
Automation
Biotechnology industry
Collaboration
Forecasts and trends
Genetic engineering
Innovations
Medical research
Medicine, Experimental
Pharmaceutical industry
Productivity
R&D
Research & development
Technological change
Technology application
Trends
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 8
container_start_page 134
container_title Pharmaceutical Executive
container_volume 26
creator Hrusovsky, Kevin
description Until 1981, pharmaceutical industry was dominated by the likes of Johnson & Johnson, Pfizer, and Merck -- all of which were established in the mid-1800s. Things were about to change. Recombinant DNA was the hot technology of the early 1980s. Genentech had just gone public after cloning insulin and then human growth hormone. In 1982, the world saw the launch of the first recombinant DNA drug -- human insulin, which Genentech had licensed to Lilly. On the other side of the block, the advent of combinatorial chemistry and automation allowed for an entirely different approach to drug discovery: high throughput screening. The industry looks quite different in the year 2006. The line between pharmaceutical and biotechnology companies grows fuzzier as these companies combine efforts via mergers and cross-licensing, and reach into the same toolbox, increasingly often, in search of better therapeutics.
format magazinearticle
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_reports_216431320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A168050925</galeid><sourcerecordid>A168050925</sourcerecordid><originalsourceid>FETCH-LOGICAL-g540-1e2f954c1965ca7543dd0069b097fec32bb08f9ba233a6c9d6d9231872818b4f3</originalsourceid><addsrcrecordid>eNotjstKAzEUQINYcKz1GxTXgZub3DyWpT4qFNx04W7Ic6hUpyZTwb-3UFdnczicC9ahIOBG0vsl6wCN45oMXLHr1j4AQCmyHbt9rMfhLu1aHH9y_b1hs-L3LS_-OWfb56ftas03by-vq-WGD6SAi4zFkYrCaYrekJIpAWgXwJmSo8QQwBYXPErpdXRJJ4dSWINW2KCKnLP7c_ZQx-9jblNf82GsU-tRaCWFRDg5D2dn8Pvc777KOFUfP0-n_VJoCwQOSf4B-Mw9lg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>216431320</pqid></control><display><type>magazinearticle</type><title>Drug discovery</title><source>ABI/INFORM Global</source><creator>Hrusovsky, Kevin</creator><creatorcontrib>Hrusovsky, Kevin</creatorcontrib><description>Until 1981, pharmaceutical industry was dominated by the likes of Johnson &amp; Johnson, Pfizer, and Merck -- all of which were established in the mid-1800s. Things were about to change. Recombinant DNA was the hot technology of the early 1980s. Genentech had just gone public after cloning insulin and then human growth hormone. In 1982, the world saw the launch of the first recombinant DNA drug -- human insulin, which Genentech had licensed to Lilly. On the other side of the block, the advent of combinatorial chemistry and automation allowed for an entirely different approach to drug discovery: high throughput screening. The industry looks quite different in the year 2006. The line between pharmaceutical and biotechnology companies grows fuzzier as these companies combine efforts via mergers and cross-licensing, and reach into the same toolbox, increasingly often, in search of better therapeutics.</description><identifier>ISSN: 0279-6570</identifier><identifier>EISSN: 2150-735X</identifier><language>eng</language><publisher>Monmouth Junction: Intellisphere, LLC</publisher><subject>Automation ; Biotechnology industry ; Collaboration ; Forecasts and trends ; Genetic engineering ; Innovations ; Medical research ; Medicine, Experimental ; Pharmaceutical industry ; Productivity ; R&amp;D ; Research &amp; development ; Technological change ; Technology application ; Trends</subject><ispartof>Pharmaceutical Executive, 2006-08, Vol.26 (8), p.134</ispartof><rights>COPYRIGHT 2006 Intellisphere, LLC</rights><rights>Copyright Advanstar Communications, Inc. Aug 2006</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/216431320?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>312,776,780,787,15295,36039,44339</link.rule.ids></links><search><creatorcontrib>Hrusovsky, Kevin</creatorcontrib><title>Drug discovery</title><title>Pharmaceutical Executive</title><description>Until 1981, pharmaceutical industry was dominated by the likes of Johnson &amp; Johnson, Pfizer, and Merck -- all of which were established in the mid-1800s. Things were about to change. Recombinant DNA was the hot technology of the early 1980s. Genentech had just gone public after cloning insulin and then human growth hormone. In 1982, the world saw the launch of the first recombinant DNA drug -- human insulin, which Genentech had licensed to Lilly. On the other side of the block, the advent of combinatorial chemistry and automation allowed for an entirely different approach to drug discovery: high throughput screening. The industry looks quite different in the year 2006. The line between pharmaceutical and biotechnology companies grows fuzzier as these companies combine efforts via mergers and cross-licensing, and reach into the same toolbox, increasingly often, in search of better therapeutics.</description><subject>Automation</subject><subject>Biotechnology industry</subject><subject>Collaboration</subject><subject>Forecasts and trends</subject><subject>Genetic engineering</subject><subject>Innovations</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Pharmaceutical industry</subject><subject>Productivity</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Technological change</subject><subject>Technology application</subject><subject>Trends</subject><issn>0279-6570</issn><issn>2150-735X</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2006</creationdate><recordtype>magazinearticle</recordtype><sourceid>M0C</sourceid><recordid>eNotjstKAzEUQINYcKz1GxTXgZub3DyWpT4qFNx04W7Ic6hUpyZTwb-3UFdnczicC9ahIOBG0vsl6wCN45oMXLHr1j4AQCmyHbt9rMfhLu1aHH9y_b1hs-L3LS_-OWfb56ftas03by-vq-WGD6SAi4zFkYrCaYrekJIpAWgXwJmSo8QQwBYXPErpdXRJJ4dSWINW2KCKnLP7c_ZQx-9jblNf82GsU-tRaCWFRDg5D2dn8Pvc777KOFUfP0-n_VJoCwQOSf4B-Mw9lg</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>Hrusovsky, Kevin</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>883</scope><scope>88C</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0F</scope><scope>M0S</scope><scope>M0T</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20060801</creationdate><title>Drug discovery</title><author>Hrusovsky, Kevin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g540-1e2f954c1965ca7543dd0069b097fec32bb08f9ba233a6c9d6d9231872818b4f3</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Automation</topic><topic>Biotechnology industry</topic><topic>Collaboration</topic><topic>Forecasts and trends</topic><topic>Genetic engineering</topic><topic>Innovations</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Pharmaceutical industry</topic><topic>Productivity</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Technological change</topic><topic>Technology application</topic><topic>Trends</topic><toplevel>online_resources</toplevel><creatorcontrib>Hrusovsky, Kevin</creatorcontrib><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Collection</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>ABI/INFORM Trade &amp; Industry</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Pharmaceutical Executive</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hrusovsky, Kevin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug discovery</atitle><jtitle>Pharmaceutical Executive</jtitle><date>2006-08-01</date><risdate>2006</risdate><volume>26</volume><issue>8</issue><spage>134</spage><pages>134-</pages><issn>0279-6570</issn><eissn>2150-735X</eissn><abstract>Until 1981, pharmaceutical industry was dominated by the likes of Johnson &amp; Johnson, Pfizer, and Merck -- all of which were established in the mid-1800s. Things were about to change. Recombinant DNA was the hot technology of the early 1980s. Genentech had just gone public after cloning insulin and then human growth hormone. In 1982, the world saw the launch of the first recombinant DNA drug -- human insulin, which Genentech had licensed to Lilly. On the other side of the block, the advent of combinatorial chemistry and automation allowed for an entirely different approach to drug discovery: high throughput screening. The industry looks quite different in the year 2006. The line between pharmaceutical and biotechnology companies grows fuzzier as these companies combine efforts via mergers and cross-licensing, and reach into the same toolbox, increasingly often, in search of better therapeutics.</abstract><cop>Monmouth Junction</cop><pub>Intellisphere, LLC</pub></addata></record>
fulltext fulltext
identifier ISSN: 0279-6570
ispartof Pharmaceutical Executive, 2006-08, Vol.26 (8), p.134
issn 0279-6570
2150-735X
language eng
recordid cdi_proquest_reports_216431320
source ABI/INFORM Global
subjects Automation
Biotechnology industry
Collaboration
Forecasts and trends
Genetic engineering
Innovations
Medical research
Medicine, Experimental
Pharmaceutical industry
Productivity
R&D
Research & development
Technological change
Technology application
Trends
title Drug discovery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T00%3A48%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20discovery&rft.jtitle=Pharmaceutical%20Executive&rft.au=Hrusovsky,%20Kevin&rft.date=2006-08-01&rft.volume=26&rft.issue=8&rft.spage=134&rft.pages=134-&rft.issn=0279-6570&rft.eissn=2150-735X&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA168050925%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g540-1e2f954c1965ca7543dd0069b097fec32bb08f9ba233a6c9d6d9231872818b4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=216431320&rft_id=info:pmid/&rft_galeid=A168050925&rfr_iscdi=true